Palvella Therapeutics Commences Phase 3 Portion of Phase 2/3 Pivotal Study of PTX-022 in Pachyonychia Congenita Wayne, PA, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare-disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...

Palvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita Wayne, PA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...

Palvella Therapeutics Announces FDA Fast Track Designation for PTX-022 for Treatment of Pachyonychia Congenita Wayne, PA, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...

Palvella Therapeutics to Present Update on PTX-022 at Pachyonychia Congenita Project Patient Support Meeting in London, UK Wayne, PA, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...

Palvella Therapeutics Appoints Rare Disease Senior Executive Elaine J. Heron, PhD to Board of Directors Wayne, PA, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...